- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04939870
Assessment of Protein Modification in Chronic Kidney Disease - Selected Clinical and Biochemical Aspects
Study Overview
Status
Intervention / Treatment
Detailed Description
Redox imbalance in the course of CKD results in the intensification of oxidative and carbonyl stress, which leads to the modification of many molecules, including proteins necessary for the proper functioning of the body. The assessment of the accumulation of modified proteins in the plasma is not only an indirect indicator of the severity of redox imbalance in the system, but also allows the analysis of the influence of oxidative stress and its derivatives (glycation, carbonyl stress and carbamylation) on the pathogenesis of CKD. In addition, compounds formed as a result of the action of ROS on proteins may affect the development of long-term consequences of CKD, such as chronic inflammation, dyslipidemia, renal osteodystrophy, iron metabolism disorders and malnutrition. On the other hand, complications in patients with CKD may influence the intensification of oxidative modifications of proteins.
The following goals were set in the study:
- Assessment of the impact of CKD advancement on the severity of protein modification as a result of oxidative stress.
- Comparison of the effect of renal replacement therapy on protein modifications.
- Assessment of the relationship between selected protein modifications in CKD and complications typical of CKD
- Comparison of selected protein modifications in patients with CKD and patients with at least one history of a cardiovascular event.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Poznań, Poland, 60-806
- Poznan University of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
The following criteria of qualifying for the study were adopted for all respondents:
- 18 years of age or older,
- written consent to participate in the study,
- no smoking for at least 10 years in the history of
- no alcohol abuse for at least 10 years in a medical history,
- lack of diabetes and impaired fasting glucose and/or impaired glucose tolerance,
- no active inflammatory process,
- no neoplastic disease or a neoplastic disease whose treatment was stopped at least 10 years ago,
- no history of immunosuppressive treatment,
- stable liver function (not more than two times increased activity of transaminases), HBs antigen and anti-HCV negative antibodies,
- anti-HIV negative antibodies.
In addition, for CKD patients, the following additional inclusion conditions were applied:
- no additional comorbidities that do not result directly or indirectly from CKD,
- no acute cardiovascular complications, ie acute heart failure, hypertensive crisis, acute coronary syndrome, at the time of study entry.
At the same time, depending on the technique of renal replacement therapy used, additional inclusion criteria were established for each of the subgroups:
in group HD:
- a minimum of 6 months of treatment with repeated hemodialysis, 3 times a week, for a minimum of 10 hours a week,
- arteriovenous fistula as a vascular access for hemodialysis,
- Estimated dialysis adequacy ratio (eKt / V) of at least 1.2. in the PD group:
- treatment duration UP to a minimum of 6 months,
- Kt / V ≥1.8 l / week / 1.73 m2.
For CARD patients, additional conditions include:
- no obvious evidence of renal impairment in the history and at the time of study entry, renal function assessed on the basis of eGFR and urine albumin/creatinine ratio,
- history of angina,
- documented history of at least one acute coronary syndrome,
- admission to the Department of Intensive Care of Cardiology and Internal Diseases in order to perform a planned coronary angiography,
- on the day of admission to the study without signs of acute coronary syndrome,
- no additional comorbidities, ie those that do not result directly or indirectly from coronary heart disease.
In turn, for the HV group, additional conditions include:
- no obvious evidence of renal impairment in the history and at the time of study entry, renal function assessed on the basis of eGFR and urine albumin/creatinine ratio,
- no obvious signs of cardiovascular impairment in the history and at the time of study entry, estimated on the basis of normal blood pressure (<140/90 mmHg), no abnormalities in the medical history and physical examination,
- not taking any medications on a regular basis.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
PREDIALYSIS GROUP
(n = 48) - patients in the pre-dialysis period (stage G3b-G4 CKD) with moderate or severe decrease in eGFR (eGFR 44-29 ml / min / 1.73 m2),
|
selected biochemical parameters
|
END-STAGE RENAL DISEASE GROUP
patients with ESRD (n=78) - (eGFR <15 ml/min /1.73 m2) undergoing renal replacement therapy.
Depending on the method of renal replacement therapy used, two subgroups are distinguished: PD subgroup (n=35) including patients treated by peritoneal dialysis.
In this subgroup, initially, due to the treatment technique, two groups were separated, a group (n=15) treated with the automatic peritoneal dialysis (APD) technique, and a group of patients (n = 20) using the technique of continuous cycling peritoneal dialysis (CCPD), HD subgroup (n = 43) including patients treated with repeated hemodialysis.
Hemodialysis procedures were performed in each patient three times a week, via an arteriovenous fistula from own or artificial vessels.
The duration of hemodialysis was at least 10 hours/week using standard bicarbonate dialysis fluids and polysulfone low-flux dialyzers.
The blood flow during hemodialysis was 200-350 ml/min, with an average dialysis fluid flow of 500 ml/min.
|
selected biochemical parameters
|
CARDIOLOGY GROUP
• CARD group (n = 37) - patients with at least one history of cardiovascular events, admitted to hospital for elective angiography, without any signs of impaired kidney function.
The studies in this group were to show the changes that occur as a result of diseases of the cardiovascular system and the functioning of the kidneys.
|
selected biochemical parameters
|
HEALTHY VOLUNTEERS
Healthy volunteers, (n = 32) - it was composed of healthy people, with no evidence of impairment in renal function and cardiovascular function in the history and at the time of enrollment in the study.
|
selected biochemical parameters
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biochemical parameters assessed in all groups part 1
Time Frame: 4 years
|
The number of laboratory parameters were determined in all groups:
|
4 years
|
Biochemical parameters assessed in all groups part 2 - selected parameters of oxidative stress
Time Frame: 4 years
|
CML [µg/mg protein], CEL [µg/mg protein], MG [µg/mg protein], AGE [µg/mg protein], RAGE [µg/mg protein] 3-NT [µmol/mg protein], AOPP [µmol/mg protein], carbonyl protein groups [nmol/mg protein], carbamyl protein groups [µg/mg protein]
|
4 years
|
Demographic data
Time Frame: 4 years
|
age [years], sex [number of female and male [n]] were recorded in all groups
|
4 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dorota Formanowicz, MD,PhD,Prof, Poznan University of Mediccal Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PoznanUMS_DF_1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on Biochemical parameters evaluation
-
University of PaviaCompleted
-
University of MonastirCompletedCardiovascular Risk Factors | FastingTunisia
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Istanbul UniversityCompletedSepsis | Septic Shock | Acute Kidney InjuryTurkey
-
Halic UniversityCompleted
-
Medical University of BialystokCompletedCognitive Functions Confusion | Suicidal Behaviour
-
IRCCS San RaffaeleRecruitingInfertility | Male InfertilityItaly
-
Atılım UniversityCompletedDown Syndrome | Gross Motor Development Delay | Congenital Heart DefectsTurkey
-
University Hospital, BordeauxInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Medical University of BialystokCompleted